Wegovy weight loss pill now available in UK - here's what you need to know
1 min read
The story
Novo Nordisk has launched an oral version of its Wegovy weight-loss drug in the UK, available privately through pharmacies without a prescription requirement for the private market. This follows the established injectable Wegovy brand and marks a meaningful step in making GLP-1 therapies more accessible — pills remove the barrier of self-injection that deters some patients.
NVO is already a dominant GLP-1 franchise with $309B in reported revenue (FY2025), 81% gross margins, and $23.03 diluted EPS, reflecting the extraordinary profitability of the semaglutide platform. The UK oral launch potentially opens a large new patient population — those unwilling to inject — and adds a recurring daily-pill revenue stream alongside the existing injectable business.
However, NVO's stock has already corrected sharply from its 2024 peaks, partly on concerns about competitive pressure from Eli Lilly's tirzepatide, pipeline setbacks, and pricing pressure risks. The oral pill launch is a positive catalyst but is not a surprise — it had been widely anticipated, and the UK is a relatively small market compared to the US opportunity where regulatory timelines differ.
The bull case rests on oral GLP-1 dramatically expanding the total addressable market if patient uptake is strong, with NVO's proven manufacturing scale and brand recognition. The bear case is that the stock is already discounting a competitive pipeline erosion scenario, and a UK-only private-pay launch is too small to move the needle on a company of this scale.
Watch for US FDA oral semaglutide approval timelines, Lilly pipeline updates, and any data on oral vs injectable efficacy comparisons — those are the real valuation-moving catalysts.
The case — both sides
With 81% gross margins, $23 diluted EPS, and an oral formulation now commercially validated in the UK, NVO's corrected valuation could re-rate higher if the pill format demonstrably expands the patient pool and the US approval pathway looks clear.
The UK launch is private-pay only in a small market and carries no surprise given prior regulatory signaling — at NVO's revenue scale of $309B, this alone is unlikely to move consensus estimates, while LLY's competing pipeline remains the dominant overhang.
The house read
Two-sidedNVO's oral Wegovy UK launch tests whether the pill format can re-rate the stock after its steep correction, or whether competitive and pricing pressures from LLY and others cap the recovery.
Wrong ifEli Lilly advances oral or injectable tirzepatide with superior efficacy data, or US FDA delays oral semaglutide approval beyond consensus timeline, both of which would reinforce the competitive narrative that has already pressured NVO.
Published read · research, not advice